NASDAQ · ZLAB
Healthcare · Biotechnology
$22.36
Down-$0.68 (-2.95%)
Updated Oct 30, 2026, 12:20 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ZLAB
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
ZLAB closed at $22.36 after 21 trading sessions, down 12.31% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $22.77 | $22.85 | $22.135 | $22.36 | 645.26K |
| Oct 28, 2026 | $23.33 | $23.49 | $22.63 | $23.04 | 704.06K |
| Oct 27, 2026 | $23.10 | $23.805 | $22.44 | $23.58 | 1.54M |
| Oct 26, 2026 | $24.38 | $24.39 | $23.02 | $24.34 | 1.74M |
| Oct 23, 2026 | $23.19 | $24.54 | $22.23 | $24.03 | 3.69M |
| Oct 22, 2026 | $22.85 | $22.88 | $21.60 | $22.04 | 1.44M |
| Oct 21, 2026 | $24.85 | $25.50 | $24.12 | $24.20 | 1.2M |
| Oct 20, 2026 | $24.20 | $25.33 | $24.095 | $25.08 | 805.47K |
| Oct 19, 2026 | $23.95 | $24.375 | $23.70 | $24.06 | 383.63K |
| Oct 16, 2026 | $24.55 | $24.64 | $23.14 | $23.19 | 843.23K |
| Oct 15, 2026 | $23.07 | $24.005 | $22.88 | $23.51 | 823.99K |
| Oct 14, 2026 | $22.30 | $22.80 | $22.12 | $22.50 | 849.72K |
| Oct 13, 2026 | $24.25 | $24.29 | $22.78 | $23.10 | 778.45K |
| Oct 12, 2026 | $24.88 | $25.00 | $24.51 | $24.59 | 524.51K |
| Oct 9, 2026 | $24.82 | $25.92 | $24.35 | $24.99 | 1.02M |
| Oct 8, 2026 | $24.33 | $24.94 | $23.76 | $24.81 | 979.23K |
| Oct 7, 2026 | $25.20 | $25.45 | $24.73 | $25.31 | 290.2K |
| Oct 6, 2026 | $26.80 | $26.92 | $25.51 | $25.58 | 1.21M |
| Oct 5, 2026 | $24.44 | $25.65 | $24.33 | $25.62 | 787.36K |
| Oct 2, 2026 | $24.86 | $24.86 | $23.71 | $24.33 | 951.85K |
| Oct 1, 2026 | $26.30 | $26.52 | $25.41 | $25.50 | 545.23K |
The latest Smart Investors Daily articles mentioning ZLAB.
Company
Market Activity
Research & News
ZLAB research
Company profile and research snapshot.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2020 | SVB Leerink | Outperform | — |
| Dec 30, 2019 | Citigroup | Buy | — |
| Sep 4, 2019 | China Renaissance | Buy | — |
| Jul 5, 2019 | Macquarie | Outperform | — |
| Jan 29, 2019 | Credit Suisse | Outperform | — |
No generated briefing is available yet.
Yahoo · Oct 23, 2026
Zai Lab (NASDAQ:ZLAB) presented early-stage data at the 2026 European Society for Medical Oncology meeting for zoci, its DLL3-targeted antibody-drug conjugate, in combination with atezolizumab, with or without carboplatin, for first-line extensive-stage small cell lung cancer. Rafael Amado, Zai Lab
Yahoo · Oct 23, 2026
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today shared the first data from a global Phase 1b clinical trial evaluating zocilurtatug pelitecan (zoci, formerly ZL-1310) in combination with atezolizumab with and without carboplatin as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). The data will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.
Yahoo · Oct 23, 2026
Zai Lab (ZLAB) said Friday its experimental drug zocilurtatug pelitecan, or zoci, combined with atez
Yahoo · Oct 23, 2026
SHANGHAI & CAMBRIDGE, Mass., October 23, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today shared the first data from a global Phase 1b clinical trial evaluating zocilurtatug pelitecan (zoci, formerly ZL-1310) in combination with atezolizumab with and without carboplatin as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). The data will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 in
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ZLAB.
